Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors.

Trial Profile

Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2016

At a glance

  • Drugs CEP 37250 (Primary)
  • Indications Adenocarcinoma; Colon cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 08 Oct 2016 Status changed from completed to discontinued according to results published in the Targeted Oncology.
    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jan 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Feb 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top